Traditional antiviral treatments, including systemic acyclovir, have shown effectiveness in resolving keratitis but can also lead to complications, including ocular surface toxicity and the development of acyclovir-resistant strains of HSV. Topical ganciclovir 0.15% ophthalmic gel presents a safer alternative for managing herpetic keratitis, offering effective viral suppression with minimal toxicity. This study aims to compare the efficacy and safety of topical ganciclovir versus systemic acyclovir in treating herpetic keratitis, providing valuable insights into optimal management strategies for this condition

Inclusion Criteria:

• Patients diagnosed with herpetic keratitis

Exclusion Criteria:

• Patients with known allergies to ganciclovir or acyclovir
• Severe ocular surface disease
• Those who have previously received antiviral therapy for herpetic keratitis within the last month